Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The treatment of tuberculosis is based on combinations of drugs that directly targetMycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.
An umbrella trial of 25 targeted treatments in all cancer types tackles treatment selection on the basis of genetic events rather than by tumour histology.
Pierre Meulien, soon to be the new Executive Director of The Innovative Medicines Initiative, discusses his plans to move the European public-private partnership forward.
This article discusses the opportunities and challenges in the application of financially adaptive clinical trials, which combine key aspects of adaptive trial design and financial analytics.
Incentives are increasingly available for the development of new drugs to tackle antibiotic resistance, but major scientific challenges remain, such as achieving penetration into bacteria. Tommasi and colleagues describe AstraZeneca's experiences in antibacterial drug discovery over the past decade using both target-based and phenotypic screening approaches, and discuss the reasons for failure as well as strategies to improve cytoplasmic penetration.
Solute carrier (SLC) transporters mediate a large number of physiological processes, and the dysfunction of individual transporters has been implicated in many Mendelian diseases. In this Review, Giacomini and colleagues summarize these roles and ways in which SLC transporters can be targeted by drugs, and highlight current and investigational drugs that modulate SLC transporters.
Anticancer immunotherapy through checkpoint blockade enables the patient to mount active antitumour responses and can dramatically improve survival. In this Review, Mahoney, Rennert and Freeman examine targets for next-generation immunomodulators and discuss how these may be integrated in rational combination therapies with existing and upcoming immune-targeted drugs.